Embecta To Discontinue Insulin Patch Pump Program And Initiate An Organizational Restructuring Plan
Embecta To Discontinue Insulin Patch Pump Program And Initiate An Organizational Restructuring Plan
Embecta計劃停止胰島素貼片泵項目，並啓動組織重組計劃
- The Company currently expects to incur total pre-tax charges of between $35 million and $45 million in fiscal year 2025 related to the restructuring plan, consisting of between $25 million and $30 million in pre-tax, cash charges for planned workforce reductions and other associated costs from the discontinuation of the patch pump program, and between $10 million and $15 million in pre-tax, non-cash charges for asset impairments and write-offs. Note, these preliminary estimates may be revised following the completion of the ongoing analysis of the expected additional pre-tax non-cash charges associated with the implementation of the restructuring plan.
- The Company expects the restructuring plan to be substantially complete during the first half of fiscal year 2025 and expects the discontinuation of the patch pump program and organizational restructuring plan to generate annualized pre-tax cost savings of between $60 million and $65 million. Given the organizational restructuring plan, the Company has decided to postpone the previously announced Analyst & Investor Day to Spring 2025.
- 該公司目前預計，2025財年與重組計劃相關的稅前費用總額在3500萬至4,500萬美元之間，其中包括2500萬至3000萬美元的稅前費用、計劃裁員的現金費用和其他因補丁泵計劃終止而產生的相關成本，以及1000萬至1500萬美元的資產減值和註銷的稅前非現金費用。請注意，在完成對與實施重組計劃相關的預期額外稅前非現金費用的分析後，這些初步估計可能會進行修訂。
- 該公司預計，重組計劃將在2025財年上半年基本完成，並預計補丁泵計劃和組織重組計劃的終止將每年節省6000萬至6500萬美元的稅前成本。鑑於組織重組計劃，公司決定將先前宣佈的分析師和投資者日推遲到2025年春季。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間